References
- WHO. Tuberculosis. WHO Press; 2019 [ updated October 17, 2019]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/tuberculosis. Accessed October 25, 2019.
- WHO. Global tuberculosis report 2019. WHO Press; 2019 [ updated October 17, 2019]. Available from: https://www.who.int/tb/publications/global_report/en/. Accessed 1021, 2019.
- WHO. Global tuberculosis report 2018. WHO Press; 2018 [ updated September 18, 2018]. Available from: https://www.who.int/tb/publications/global_report/en/. Accessed 917, 2019.
- Dheda K, Gumbo T, Maartens G, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017;5(4):291–360. doi:10.1016/S2213-2600(17)30079-6
- Dheda K, Warren RM, Zumla A, Grobusch MP. Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infect Dis Clin North Am. 2010;24(3):705–725. doi:10.1016/j.idc.2010.05.00120674800
- Wang L, Zhang H, Ruan Y, et al. Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data. Lancet (London, England). 2014;383(9934):2057–2064. doi:10.1016/S0140-6736(13)62639-2
- Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012;366(23):2161–2170. doi:10.1056/NEJMoa110878922670902
- Ding P, Li X, Jia Z, Lu Z. Multidrug-resistant tuberculosis (MDR-TB) disease burden in China: a systematic review and spatio-temporal analysis. BMC Infect Dis. 2017;17(1):57. doi:10.1186/s12879-016-2151-528073344
- WHO. Global health observatory data repository; 2019 [ updated September 2, 2019]. Available from: http://apps.who.int/gho/data/view.main.57040ALL?lang=en. Accessed 916, 2019.
- WHO. The End TB Strategy-Global strategy and targets for tuberculosis prevention, care and control after 2015. WHO Press; 2018 [ updated September 18, 2018]. Available from: https://www.who.int/tb/strategy/End_TB_Strategy.pdf. Accessed 917, 2019.
- General Office of the People’s Republic of China. 13th Five-Year National Tuberculosis Control Plan; 2017 Available from: http://www.gov.cn/zhengce/content/2017-02/16/content_5168491.htm#. Accessed 916, 2019.
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England). 2018;392(10159):1789–1858. doi:10.1016/S0140-6736(18)32279-7
- Murray CJ, Ezzati M, Flaxman AD, et al. GBD 2010: design, definitions, and metrics. Lancet (London, England). 2012;380(9859):2063–2066. doi:10.1016/S0140-6736(12)61899-6
- Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Results. Institute for Health Metrics and Evaluation (IHME); 2018 Available from: http://ghdx.healthdata.org/gbd-results-tool. Accessed 916, 2019.
- Surveillance Epidemiology and End Results (SEER) Program. World (WHO 2000–2025) Standard; 2013 Available from: https://seer.cancer.gov/stdpopulations/world.who.html. Accessed 916, 2019.
- Wang Y.. Technical Guidance Group of the Fifth National TB Epidemiological Survey, The Office of the Fifth National TB Epidemiological Survey. The fifth national tuberculosis epidemiological survey in 2010. Chin J Antituber. 2012;34(8):485–508.
- Zhao F, Du X, Li T, et al. Epidemic trend and prediction analysis of tuberculosis based on WHO public database in China. Clin Med J. 2018;16(4):1–3.
- Lin HH, Wang L, Zhang H, Ruan Y, Chin DP, Dye C. Tuberculosis control in China: use of modelling to develop targets and policies. Bull World Health Organ. 2015;93(11):790–798. doi:10.2471/BLT.15.15449226549907
- Zeng Y, Yang X, Zhou H, Pu L. Disease Burden of tuberculosis in the Chinese population: a systematic review. Chinese J Evid Based Med. 2018;6:570–579.
- Gao L, Lu W, Bai L, et al. Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis. 2015;15(3):310–319. doi:10.1016/S1473-3099(14)71085-025681063
- Zhang J, Gou H, Hu X, et al. Status of drug-resistant tuberculosis in China: a systematic review and meta-analysis. Am J Infect Control. 2016;44(6):671–676. doi:10.1016/j.ajic.2015.12.04226944006
- Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet (London, England). 2010;375(9728):1830–1843. doi:10.1016/S0140-6736(10)60410-2
- Dheda K, Gumbo T, Gandhi NR, et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med. 2014;2(4):321–338. doi:10.1016/S2213-2600(14)70031-124717628
- Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS One. 2013;8(1):e54587. doi:10.1371/journal.pone.005458723349933
- Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med. 2015;5(9):a017863. doi:10.1101/cshperspect.a01786325918181
- Dheda K, Gumbo T, Maartens G, et al. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respir Med. 2019;7(9):820–826. doi:10.1016/S2213-2600(19)30263-231486393